[Action of 17-hydroxyprogesterone caproate on the glandular hyperplasia of human endometrium].
The effect of 17-oxyprogesterone capronate on the proliferative activity and metabolic processes in the endometrium of patients with glandular hyperplasia of the endometrium was studied. It was shown that the proliferative activity was inhibited while the secretory processes in the glandular epithelium were activated. This effect was achieved only after a long-term (6-9 months) administration of the hormone.
D000328:Adult; D002455:Cell Division / Q000187:drug effects; D004341:Drug Evaluation; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D004717:Endometrium / Q000187:drug effects* / Q000503:physiopathology; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007620:Karyometry; D008875:Middle Aged; D013997:Time Factors; D014592:Uterine Hemorrhage / Q000188:drug therapy
D006908:Hydroxyprogesterones; D006003:Glycogen
Izuchenie deĭstviia 17-oksiprogesterona kapronata na zhelezistuiu giperplaziiu éndometriia cheloveka.